This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks
by Trina Mukherjee
With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.
Quest Diagnostics (DGX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Quest Diagnostics (DGX) could produce exceptional returns because of its solid growth attributes.
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks
by Urmimala Biswas
According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.
West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs
by Zacks Equity Research
Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs
Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Value Stocks Based on Discounted PEG to Buy Now
by Urmimala Biswas
Here are five stocks, OLN, DGX, EQNR, TECK, and GS that qualify the screening.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics (DGX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Quest Diagnostics (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.